Fig.1.

Initially 577 subjects were considered for inclusion, whereof 87 did not fulfill inclusion criteria or withdrew before finishing the assessment program. 465 subjects were staged, as either normal controls (NC), normal controls with first degree relative (NCFD), controls with abnormal cognitive screening results (ACS), subjective cognitive decline (SCD) or mild cognitive impairment (MCI). At the time of analysis, APOE genotyping was available for 445 subjects, whereof 202 were APOE ɛ4 positive. Cerebrospinal fluid data was available for 411 subjects, whereof 96 subjects had pathological levels of Aβ₄₂.